Introduction
The current understanding of the roles of acetylation in the epigenetic regulation of chromatin structure, and gene expression rests on the balance of activities of histone acetyltransferases (HATs) and histone deacetylases (HDACs). Increased acetylation of histones leads to changes in chromatin structure and accessibility for key cellular proteins to specific target sites (1, 2) . HATs acetylate lysine groups at the amino terminal tails of nuclear histones to neutralize positive charges on the histones, yielding a more open, transcriptionally active chromatin structure (3) . In contrast, the HDACs deacetylate and suppress transcription. In this model, inhibitors of HDACs bias the balance toward a more acetylated state. Such a shift in the relative activities of these enzymes may change gene expression necessary for DNA repair, replication, cell cycle checkpoint activation and tumor suppression (4, 5) .
Human histone deacetylases can be divided into four classes based on structure, sequence homology, and domain organization. Class I consists of HDACs 1, 2, 3, and 8. Class I HDACs are nuclear and play roles in cell proliferation and apoptosis. Class II includes HDACs 4, 5, 6, 7, 9 , and 10 (6). These enzymes are characterized by a large NH 2 -terminal domain or a second catalytic site and their expression is more restricted, suggesting roles in cellular differentiation and development (2) . Class III enzymes include the SIRTs (sirtuins), and are NAD-dependent deacetylases (7) . Class III enzymes are not inhibited by TSA or other hydroxamates. HDAC11 is designated as Class IV based on phylogenetic analysis (8) .
HDACs are found in the nuclear and cytoplasmic compartments. Although they are approximately 400 amino acids and zinc binding sites. It is the core domain that presents the principal target for design of inhibitory small molecules. Key reported acetylation mechanisms relevant to cancer treatment have involved histones and tubulin, as well as a variety of other non-histone proteins (9) (10) (11) (12) . We have reported radiation sensitizing properties of novel hydroxamic acid and mercaptoacetamide inhibitors in a search for HDAC isomer specificity (13, 14) . By designing and synthesizing new class II targeting HDAC inhibitors offering intrinsic fluorescent properties, we provide further insight into action mechanisms and sub-cellular sites of inhibitor activities.
Materials and Methods: Materials
HeLa nuclear extracts and fluorimetric histone deacetylase assay kits were obtained from BIOMOL (Plymouth Meeting, PA). Antibodies for acetylated α-tubulin and HDAC4 were purchased from Sigma, acetylated histone H4 from Upstate Biotechnology (Lake Placid, NY), and GAPDH from Trevigen (Gaithersburg, MD).
As a quality control and in order to confirm the identity of the cultured cell lines used in these experiments, cell lines were submitted to genetic fingerprinting. The commercially available Cell IDTM System (Promega) was used to screen cell lines obtained from the Georgetown Tissue Culture Shared Resource (LNCaP). Cells which were obtained from the ATCC (A549, MCF7, C42, PC-3) were genetically fingerprinted using the PowerPlex 1.2 System by the ATCC and have been passaged for less than six months before use in these experiments. All cell lines were screened for the presence of mycoplasmids prior to use by the 
Synthesis
Schemes, methods of syntheses and spectroscopic data for the new compounds are presented in the supplementary material. Purity and identity were established for all compounds using mass spectrometry, NMR spectrometry and HPLC analyses.
HDAC Assays
The values of IC 50 concentrations of HDAC inhibitors were determined performing a fluorimetric histone deacetylase assay following the manufacturer's instructions. For the pan-HDAC assay, HeLa nuclear extracts were used as a source of histone deacetylase, and the histone deacetylase isomer inhibition assays were performed using purified recombinant histone Cell lines PC-3 (prostate cancer), C42 (androgen-independent prostate cancer), and LNCap (androgen-dependent prostate cancer) were cultured in RPMI-1640 medium supplemented with 100 mg/mL of streptomycin, 100 mg/mL of penicillin, 2 mM L-glutamine, 1 mg/mL of hydrocodisone, and 20% fetal bovine serum. These cultures were maintained in a 95% air/5% CO 2 incubator at 37 °C. After 24 hours seeding, a solution of the compound or DMSO vehicle control were added to cells and incubated for 48 hours at 37 °C. 
Cell Cycle Distribution
LNCap and PC-3 cells were incubated in the presence or absence of compound prior to harvesting at the indicated time points, washed twice with cold phosphate-buffered saline, and 1-2 × 10 6 cells were resuspended in 0.5 mL of ice-cold phosphate-buffered saline for analysis.
Single cell suspensions were verified microscopically. The cell suspension was gradually mixed with ice-cold absolute ethanol to the final volume of 2.0 mL, and cooled on ice at least for 20 min before staining with propidium iodide. The cell cycle distributions were measured in a fluorescence-activated cell sorter from Becton Dickinson. DNA content levels were quantified using ModFit LT 3.0 software (Verity Software House, Inc.).
Fluorescent Measurement
Cells were plated onto glass slides at a density of 500,000 per slide and incubated 
Western Blot Analysis
Cells were treated 24 hours after seeding with compound (dissolved in DMSO) at the concentration of (0.1, 1, 5, 10 and 50 μM), equal amount of DMSO was added to the control groups. After incubation at 37 °C, the cell culture media was removed and washed once with fresh media, then, HDAC compounds were added to the cell culture. The cell culture was kept at 37 °C for another 24 hours, then harvested. 
Results

Rational Drug Design and Molecular Modeling
We developed homology models to represent HDAC isomers based on the observation that each HDAC is unique in the CAP region. Substitution of bulky cap groups potentially offers increased selectivity and potency, and the site is capable of accommodating a large fluorescent probe. Docking simulations of compounds 1-4 ( Figure 1A 
Synthesis of Compound 2 and Analogs
The strategy for synthesis of fluorescent molecule 2 and analogs containing various length linkers is outlined in Supplemental Figure 1 . In general, dansyl chloride was reacted with the appropriate amino carboxylic acid to yield the dansylated derivative acid 5-8 in high yield.
Using an EDCI-HOBT combined condensation, acids 5-8 were activated and condensed with benzyloxyamine to yield amides 9-12. Hydrogenation of 9-12 provided the final hydroxamic acid products 1-4 with yields over 90%. 
Screening for HDAC Inhibitory Activity
In vitro pan-HDAC activity inhibition assays were performed as the initial screen to assess overall compound potencies. Compound 2 and 3 are effective pan-HDAC inhibitors with IC 50 values of 125 nM and 116 nM, respectively as compared to compounds 1 and 4 ( Table 1 ).
The inhibitory activities of these compounds were linker-length dependent. The four and seven carbon spacers (compound 1 and 4) were less active than were the five and six carbon linkers (compound 2 and 3), which allowed appropriate positioning of the hydroxyamic acid and the dansyl fluorophore within the hydrophobic cavity ( Figures 1B-D) .
HDAC inhibitory potency of compound 2 was also maintained by substituting a sulfonamide in the linker unit in place of a carbonylamide. The dansyl moiety is exposed in the CAP region and forms vertical pi-pi stacking interactions with surrounding hydrophobic residues.
Compound 3 contains a six carbon spacer flexibly positioned into the hydrophobic cavity with hydrogen bonding similar to that of compound 2 (Structure figure not shown), however, the seven carbon linker in compound 4 does not position the dansyl group optimally (figure not shown). Although the four carbon spacer of compound 1 fits well into the hydrophobic site, the lack of H-bond formation of the amide group (contained in the dansyl moiety) with the surface residues results in low affinity (Table 1 ). These data demonstrate that compounds containing dansyl groups in the cap regions offer effective inhibition of HDACs.
The compounds fall well within the rules proposed by Lipinski (15) and we also note that the polar surface areas of the compounds are all greater than 150 Å 2 . Measurements of the excitation and emission spectra for compounds 1-4 document the fluorescence properties of the HDAC inhibitors (Table 1) . 
HDAC Isomer Specificity
Observations of non-overlapping functions for HDAC isomers present an opportunity for achieving therapeutic specificities. Compounds 2 and 3 were evaluated for inhibitory effects on recombinant proteins available for ten of the class I and II HDAC isomers. As summarized in Table 2 , compounds 2 and 3 show increased inhibition of class II HDAC isomers. Of note, HDAC6 is a microtubule associated protein that can deacetylate α-tubulin in vitro. Also, HDAC6
has been reported to interact with β-tubulin in vitro (16) . This dual deacetylase function of HDAC6 may offer a research tool to study cellular function of HDACs. Because HDAC6 localizes predominantly in the cytoplasm and deacetylates tubulin, we considered it as functionally distinct from other known HDACs, and focused on substrates other than histones. 
Cell Growth Inhibition and Cell Cycle Distributions
As promising targets for cancer treatment, HDAC inhibitors have shown significant antiproliferative and apoptotic activities on various cancer cells, including prostate cancer (17) (18) (19) . (Table 3) . This effect was observed in both androgen dependent and independent prostate cancer cells. We also evaluated compound 2 against additional human cancer cell lines MCF7 and A549 (Table 3 ). The effects of our compound on cell cycle distributions were similar to that observed with SAHA.
Imaging Compound 2 in Human Prostate Cancer Cells
Utilizing the inherent fluorescent properties of our compound, we imaged compound 2 in localized to the cytoplasm. Co-localization experiments with propidium iodide reveal that compound 2 does not localize to nuclei (Figure 2A ).
Imaging the Effects of Compound 2 on Histone Acetylation
Next, we determined the effects of compound 2 on histone acetylation in A549 cells.
A549 cells were treated with 20 µM of compound 2, allowing comparisons to previously published data (20) and evaluation of this novel compound in other cancer cell types. Figure 2B demonstrates that compound 2 increases acetylation of nuclear histones, a marker of the functional effect on the enzyme as compared to controls which was not shown clearly in the literature ( Figure 2B(f) ) (20) . Interestingly, compound 2 localized to the cytoplasm ( Figure   2B 
Imaging the Effects of Compound 2 on Non-Histone Protein
Class II HDACs shuttle between the nuclei and cytoplasmic compartments of cells, and modify the acetylation status of tubulin residing in the cytoplasm. Compound 2 also caused an increase in α-tubulin acetylation ( Figure 2C ) in the cytoplasms of A549 cells as compared to control ( Figure 2C(e) ). As shown in experiments using other cell lines, compound 2 fluoresced in the cytoplasms of these cells as well ( Figure 2C(b) ).
Mechanistic Studies on HDAC4 Interactions with Compound 2
HDAC isomers demonstrate non-redundant functions. HDAC6 is a microtubule associated protein that deacetylates tubulin in vitro. The expression of HDAC6 has been reported exclusively in the cytoplasm (23) . HDAC10 was found to be the closest relative of HDAC6, but it has an incomplete second HDAC domain (24) (25) (26) . Other class II HDACs, for example HDAC4 and HDAC5, have been found to shuttle between the nucleus and the cytoplasm (27, 28) , whereas HDAC7 shuttling is not certain. This correlates to the observations that compound 2 is potent in inhibiting HDAC 4, 5, 6 and 10, and also has shown activity against HDAC11, which combines properties of both class I and class II HDACs (Table 2) . We interpret these data to show that compound 2 affects the functions of the nuclear HDAC enzymes without entering the nucleus.
Compound 2 fluorescence was detected in the cytoplasm; therefore, we sought to evaluate its interactions with HDAC's capable of shuttling from the nucleus into the cytoplasm.
HDAC4 was selected as the model HDAC for these studies given its known cytoplasmic-nuclear shuttling (29) and the potency (IC 50 , Table 2 
in a significant reduction of HDAC4 in the nucleus, DAPI staining of the nucleus confirmed depletion of HDAC4 ( Figure 3B ). Interestingly, in control experiments, SAHA also depleted the nucleus of HDAC4 ( Figure 3C) . As a control, we evaluated by western analysis of five HDAC isomers including HDAC1 and 2 and found no change in protein concentration up to 50 μM dose (See supplemental Figure 3 ). In addition, PC3 cells treated with compound 2 and immunostained for HDAC1, continued to show HDAC1 in nucleus (See supplemental Figure 4 ).
These observations demonstrate the utility of the new HDAC ligand and point to potential new interpretations of mechanisms for inhibition of nuclear HDAC-mediated deacetylation.
The transcription of p21 is regulated through acetylation of histone. Acetylation of histones results in increased p21 transcription. Hence, the expression levels of p21 reflect the inhibitory effects on HDAC's by these compounds. PC3 cells do not express p53, resulting in decreased p21 levels (30, 31) . T24 cells (human bladder cancer cells) were used to check the expression levels of p21 following treatment with compound 2. Exposure of T24 cells to 5 μM of compound 2 resulted in up-regulated expression of p21 ( Figure 4A ). p21 binds to and inhibits cyclin-CDK2 resulting in G1 arrest (32). Compound 2 caused G1 arrest in PC3 and LNCaP cells (Table 3) . Since PC3 cells do not express p53, these data suggest the presence of an alternative pathway to G1 arrest.
HDACs play important roles in regulating other cellular activities. Class II HDAC shuttle between the nuclei and cytoplasm, and modify the acetylation status of tubulin residing in the cytoplasm. When PC3 cells were treated with compound 2 or with SAHA, the acetylation levels of tubulin ( Figure 4B ) and H3 ( Figure 4C ) were increased. This further supports our findings with the HDAC isomer inhibition assay (Table 2) HDAC6 is known to affect protein stability (33), a potentially increasing degradation of class I HDACs. We evaluated five HDAC isomers including HDAC1, 2, 3, 4 and 5 and observed no changes in protein levels up to 50 μM exposure (Supplemental figure 3) .
Discussion
In this study we have designed and synthesized novel fluorescent HDAC inhibitors. We Figure 1A . 
